Compare Dollar Tree, Inc. (DLTR) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Mesoblast Limited — how do they compare? Dollar Tree, Inc. trades at $118.65 (market cap $21.82B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Dollar Tree, Inc. is far larger — about 12.1× Mesoblast Limited's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and Mesoblast Limited for 14 Days on average.
| DLTR | MESO | |
|---|---|---|
Market Cap | $21.82B | $1.81B |
Volume | 1,613,659 | 240,620 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $20.96 |
52-Week Low | $86.80 | $13.19 |
Typical Hold Time | 58 Days | 14 Days |
Enterprise Value | $28.43B | $1.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $118.62, up 2.09% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 45.87% ROE and trades at a modest P/E of 14.25. Recent news highlights strategic initiatives and store expansions driving growth, though margin risks from tariffs and costs persist. Cash flow trends are positive, with 2025 net cash flow reaching $754 million.
Outlook is positive with a consensus price target of $139.33, implying 17% upside. Key opportunities include continued earnings momentum and store improvements, while risks involve margin pressure from tariffs and reinvestment costs. Analyst sentiment is bullish with 53% buy ratings, but investors should monitor execution on profitability targets.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
